哈佛癌症中心（DF/HCC）是NCI指定的综合性癌症中心，通过整合和建立哈佛癌症研究界的集体人才和资源，由波士顿五所学术医疗机构——贝丝·以色列女执事医疗中心、波士顿儿童医院、布莱根妇女医院、丹娜-法伯癌症研究所和马萨诸塞州总医院以及哈佛医学院和哈佛大学陈曾熙公共卫生学院共同支持构成。机构结合彼此的科学优势，创造了一个超越机构边界的丰富协作环境。DF / HCC是丹娜-法伯癌症研究所综合癌症中心的强大继承组织，该中心是NCI于1973年指定的原始癌症中心之一。
跨学科研究计划促进了来自五所学术医疗机构和两所哈佛健康科学学院的成员在人口、基础、转化和临床研究方面的合作。具有成本效益的共享设施或集中式核心实验室使研究能够获得尖端技术，并建立世界一流的科学档案。作为全球最大的癌症研究企业之一，DF/HCC致力于最大限度地发挥其研究对癌症患者的影响，最终实现一个没有癌症的世界。
中心关注临床研究和学科理论研究，包括乳腺癌、胃肠道恶性肿瘤、肾癌、白血病、肺癌、淋巴瘤、癌症风险预防、癌症免疫学、发育治疗学等。此外，中心的研究领域包括血管生成、侵袭和转移、头颈部癌症、影像学、护理、姑息治疗、肉瘤、存活和病毒肿瘤学。
The Harvard Cancer Center (DF/HCC) is an NCI-designated comprehensive cancer center, and by integrating and building the collective talent and resources of the Harvard cancer research community, It is supported by five academic medical institutions in Boston -- Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Massachusetts General Hospital, as well as Harvard Medical School and Harvard T.H. Chan School of Public Health. Institutions combine each other's scientific strengths to create a rich collaborative environment that transcends institutional boundaries. DF/HCC is a strong successor organization to the
Dana-Farber Cancer Institute Comprehensive Cancer Center, one of the original cancer centers designated by the NCI in 1973.
The Interdisciplinary Research Program fosters collaboration in demographic, basic, translational, and clinical research among members from five academic medical institutions and the two Harvard Schools of Health Sciences. Cost-effective shared facilities or centralized core laboratories enable research to gain access to cutting-edge technologies and build world-class scientific archives. As one of the world's largest cancer research enterprises, DF/HCC is committed to maximizing the impact of its research on cancer patients and ultimately achieving a cancer-free world.
The CENTER focuses on clinical research and academic research, including breast cancer, gastrointestinal malignancies, renal cancer, leukemia, lung cancer, lymphoma, cancer risk prevention, cancer immunology, developmental therapeutics, etc. In addition, the Center's research areas include angiogenesis, invasion and metastasis, head and neck cancer, imaging, nursing, palliative care, sarcoma, survival, and viral oncology.